Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
The WHO's TAG-CO-VAC is gearing up for its December 2026 meeting to decide which SARS-CoV-2 variants should shape the next round of COVID-19 vaccines. The group is calling on scientists and manufacturers to submit immunological, virological, and vaccine effectiveness data on key variants like LP.8.1, NB.1.8.1, and XFG. The goal: make sure the next vaccine formula stays ahead of the virus.
The WHO's Technical Advisory Group on COVID-19 Vaccine Composition (TAG-CO-VAC) is preparing for its December 2026 meeting, where it will decide whether current COVID-19 vaccines need an antigen update. In a new statement, the group is urging researchers and vaccine manufacturers to prioritize generating and sharing specific data to ensure the decision is grounded in the latest science.
The TAG-CO-VAC is particularly focused on several circulating and emerging SARS-CoV-2 variants, requesting neutralization data, immune response breadth and durability assessments, and real-world vaccine effectiveness estimates tied to these strains.
Key Takeaways:
Why it matters: Keeping COVID-19 vaccines matched to circulating variants is critical for maintaining protection at the population level. This call for data is the first step in a transparent, evidence-driven process that directly shapes which vaccine formulas will be authorized globally — affecting millions of people heading into 2027.
